Summary of the technology
Research groups from the Department of Organic Chemistry and Inorganic Chemistry and the Department of Systems Biology of the University of Alcalá have developed pyridazino[2,3-a]pirrolo[2,1-c]-quinoxalinium salts as therapeutic agents in the treatment of leishmaniasis, metabolic syndrome, diabetes and obesity. The compounds exhibit high activity and selectivity for the Leishmania parasite, and they provide a new therapeutic tool for the treatment of type 2 diabetes.
The group seeks pharmaceutical companies to reach licensing agreements or collaboration and commercial agreements with technical assistance.
New and innovative aspects
As leishmanicidal, these compounds are highly selective. They can be used with other pharmaceuticals or additional active principles to provide a combination therapy.
As inhibitors of PTP1B, these compounds provide a new pharmacophore structure.
Main advantages of its use
High specificity for the Leishmania parasite.
Possible new therapy for diabetes and obesity.
Specifications
- The invention relates to the preparation of new compounds of Formula I as well as to the uses of these compounds to inhibit the growth and infection of the Leishmania parasite, which is an important new tool from the medical and veterinary point of views.
- The invention also relates to the use of these compounds to inhibit PTP1B (protein belonging to the family of protein tyrosine phosphatases, PTPs).
The composition comprises at least one of the compounds of the invention together with a pharmaceutically acceptable carrier. The use of this composition for the treatment of infectious diseases is as a therapeutically effective amount. It can be prepared as a solid or aqueous suspension, in an acceptable pharmaceutically solvent and may be administered by a suitable administration route. The compounds of the invention are prepared from pirroloquinoxalines.
It can be used for the treatment of insulin resistance, glucose intolerance, obesity, diabetes mellitus, hypertension and ischemic diseases. Moreover, these compounds can be used in the treatment of cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involved with inflammation and the immune system.
The present invention also concerns the use of these compounds for the treatment of renal failure, myocardial infarction, ischemia, multiple sclerosis, neurodegenerative diseases or infectious diseases such as leishmaniasis.
Applications
- Production of an active principle for the formulation of a leishmanicidal medicament.
- Production of an active ingredient for the formulation of a medicament for the treatment of metabolic syndrome, diabetes and obesity.
Intellectual property status
Patent granted
Current development status
Development phase
Desired business relationship
The group seeks pharmaceutical companies to reach licensing agreements or collaboration and commercial agreements with technical assistance.
Related keywords
![Salts of pyridazino[2,3-a]pyrrolo[2,1-c]quinoxaline for the treatment of leishmania infections and diseases that involve the protein tyrosine phosphatise 1B (metabolic syndrome, diabetes and obesity)](https://static8.innoget.com/uploads/thumb//uploads//3df023970d7a042a76c022ad05180fd34bba60d6.jpg)
